How should low ferritin be evaluated and managed?

Evaluation and Management of Low Ferritin

Begin oral iron supplementation immediately with ferrous sulfate 65 mg elemental iron daily (or alternate-day dosing) while simultaneously investigating the underlying cause, because low ferritin represents depleted iron stores that warrant treatment even before anemia develops. 1

Diagnostic Thresholds and Interpretation

Ferritin cutoffs for confirming iron deficiency:

• Ferritin <15 μg/L has 99% specificity for absolute iron deficiency—this definitively confirms the diagnosis without need for additional testing 1, 2
• Ferritin 15-30 μg/L indicates depleted body iron stores and generally warrants treatment 1, 3
• Ferritin <45 μg/L provides optimal sensitivity-specificity balance (92% specificity) for clinical decision-making 1, 2

Critical caveat—inflammation masks true iron deficiency:

• Ferritin is an acute-phase reactant that rises during infection, inflammation, or tissue damage, potentially concealing depleted iron stores 1
• In patients with chronic inflammatory conditions (IBD, CKD, heart failure, cancer), use a higher threshold of ferritin <100 μg/L to diagnose iron deficiency 1, 3
• Always check C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) when ferritin is 30-100 μg/L to determine if inflammation is falsely elevating ferritin 1

Calculate transferrin saturation (TSAT) to assess iron availability:

• TSAT = (serum iron × 100) ÷ total iron-binding capacity 1
• TSAT <16-20% confirms iron deficiency even when ferritin appears normal or elevated due to inflammation 1, 2
• TSAT reflects iron readily available for red blood cell production, whereas ferritin reflects storage iron 1

Investigation of Underlying Causes

Mandatory screening for all patients with iron deficiency:

• Screen for celiac disease with tissue transglutaminase IgA antibodies—celiac disease accounts for 3-5% of iron deficiency cases and causes treatment failure if missed 1, 3
• Test for Helicobacter pylori infection using stool antigen or urea breath test, as the organism impairs iron absorption 1, 3

Indications for bidirectional endoscopy (upper GI gastroscopy + colonoscopy):

• All adult men and postmenopausal women with iron deficiency require urgent endoscopy, because iron deficiency may be the sole manifestation of gastrointestinal malignancy 1, 2
• Age ≥50 years (higher malignancy risk) 1
• Gastrointestinal symptoms (abdominal pain, altered bowel habits, visible blood) 1
• Positive celiac or H. pylori testing requiring confirmation 1
• Failure to respond to adequate oral iron after 8-10 weeks 1, 3
• Strong family history of colorectal cancer 1

For premenopausal women <50 years:

• GI investigation is conditional rather than mandatory if heavy menstrual bleeding is present and no alarm symptoms exist 1
• Empiric oral iron supplementation without immediate endoscopy is appropriate in young women with heavy menses, negative celiac/H. pylori testing, and no GI symptoms 1

Oral Iron Supplementation Protocol

First-line therapy for most patients:

• Ferrous sulfate 65 mg elemental iron daily, or 60-65 mg every other day—alternate-day dosing improves absorption by 30-50% and reduces gastrointestinal side effects 1, 2, 3
• Alternative formulations if ferrous sulfate is not tolerated: ferrous bisglycinate (30-60 mg elemental iron daily) or ferrous gluconate/fumarate at equivalent doses 1
• Take on empty stomach for optimal absorption, or with meals if gastrointestinal symptoms occur 1
• Expected side effects include constipation, nausea, or diarrhea; approximately 50% of patients have decreased adherence due to adverse effects 2

Expected therapeutic response:

• Hemoglobin should rise by ≥10 g/L within 2 weeks of starting therapy 1, 2
• Reticulocytosis occurs within 3-5 days in responsive patients 1
• Absence of hemoglobin rise suggests malabsorption, non-compliance, or ongoing blood loss 1

Duration of therapy:

• Continue oral iron for 3 months after hemoglobin normalizes to achieve target ferritin >100 ng/mL and fully restore iron stores 1, 3
• Iron stores require 3-6 months to replenish after bleeding stops, provided adequate supplementation is maintained 1
• During weeks 2-8, hemoglobin typically normalizes while ferritin remains low because absorbed iron is preferentially used for red cell production 1

Indications for Intravenous Iron Therapy

Switch to IV ferric carboxymaltose (15 mg/kg, maximum 1000 mg per dose) when:

• Oral iron intolerance (marked nausea, constipation, diarrhea) 1, 3
• Confirmed malabsorption (celiac disease, inflammatory bowel disease, post-bariatric surgery) 1, 3
• Ongoing blood loss exceeding oral replacement capacity 1, 3
• Chronic inflammatory conditions (CKD, heart failure, IBD, cancer) 1, 3
• Pregnancy in second/third trimester 1, 3
• Lack of hemoglobin response after 8-10 weeks of adequate oral iron 1, 2

Efficacy of IV iron:

• Produces reticulocytosis within 3-5 days 1
• Yields mean hemoglobin increase of approximately 8 g/L over 8 days 1
• Hypersensitivity to newer IV iron formulations is rare (<1%) 2
• In hemodialysis patients receiving erythropoiesis-stimulating agents, maintain ferritin >200 ng/mL and TSAT >20% to optimize hemoglobin response 4

Follow-Up and Monitoring

Short-term monitoring:

• Repeat complete blood count and ferritin at 8-10 weeks to assess response to treatment 1, 2, 3
• Persistent failure of ferritin to rise despite adequate supplementation signals ongoing blood loss or malabsorption and warrants urgent GI evaluation 1

Long-term monitoring for high-risk populations:

• For menstruating females, vegetarians, athletes, and regular blood donors, screen ferritin every 6-12 months to detect early depletion before anemia develops 1, 3
• Menstruating females require twice-yearly screening; males require annual screening 1

Critical Pitfalls to Avoid

• Do not assume normal ferritin excludes iron deficiency in inflammatory states—check TSAT, which remains low (<20%) even when inflammation falsely elevates ferritin 1
• Do not discontinue iron therapy once hemoglobin normalizes—an additional 3 months of supplementation is required for ferritin to reach >100 ng/mL 1
• Do not overlook celiac disease screening (3-5% prevalence in iron deficiency), as missing this diagnosis leads to treatment failure 1, 3
• Do not delay endoscopic evaluation in high-risk patients (age ≥50, alarm symptoms, treatment failure), as GI malignancy can present solely with iron deficiency 1, 2
• Do not continue daily iron supplementation once ferritin normalizes, as this is potentially harmful 1, 5
• Do not assume dietary iron alone will replenish stores—supplementation is required for clinically acceptable repletion 1